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Mutations in the POLG1 gene are considered to be the most common gene defect identified in autosomal
recessive mitochondrial DNA depletion disorders [1]. POLG1 is a gene encoding the 195kDa catalytic (alpha)
subunit of the mitochondrial (gamma) DNA polymerase, located on chromosome 15q25 and is responsible for
mtDNA replication [1]. Mutations in POLG1 are associated with highly variable phenotypes. The vast majority
of pathogenic mutations in POLG1 have been associated with chronic progressive external ophthalmoplegia
(CPEO) [2]. Other genes that have been implicated in causing syndromic and non-syndromic mitochondrial
disorders have been found on both mtDNA (3243A>G, 8344A>G, 8993T>G, and 11778A>G) and nDNA
(SURF1, POLG1, TWINKLE, and ANT1) [3].
We report a patient with a rare type of POLG1 gene (A467T/W748S) mutation with a wide range of neurological
manifestations, including, focal parieto-occipital lobe seizures, sensory axonal neuropathy, intestinal malabsorption, and impairment of visual perception and other cognitive domains. Mitochondrial disorders can have
a very insidious clinical course, which can make the diagnosis difficult especially if genetic workup for routinely
tested mitochondrial disorders is negative. Treatment of the epilepsy in patients with POLG1 gene mutations,
specifically the compound heterozygous A467T/W748S, can be very challenging. While some conventionally
used anti-seizure medications can turn out to be ineffective, others such as valproic acid can have deleterious
effects on neurological function and make the seizures worse.

Case Report
•A 16-year-old woman, who was an ex-preemie (GA 36 weeks) born by C-section after spontaneous rupture of
membranes to non-consanguineous parents, developed over a one year period progressively worsening focal
seizures refractory to oxcarbazepine, levetiracetam, and zonisamide. Topiramate was started but the patient
developed cognitive side effects and was therefore stopped. Valproic acid was initiated which made the patient’s
cognitive symptoms and seizures worse, at which time the patient presented to our epilepsy monitoring unit with
focal status epilepticus. Before the seizures started, the patient had done well in school with no learning
disabilities. The patient had denied any known seizure risk factors and had no past medical history except for
migraine headaches, depression, and anxiety. As an infant she had episodes of back arching and crying spells
of long duration. As a toddler she had fear episodes with a sensation that the ceiling was falling down on her. In
kindergarten she had episodes of starring spells. The patient had normal emergence of speech and ambulation.
•She described three seizure types: Focal twitching of the right face, arm, and leg followed sometimes by loss of
awareness and a secondary generalized tonic-clonic convulsion with right head version lasting less than five
minutes, which was followed by residual weakness on the right side and post-ictal confusion. The first seizure
type would occur at a frequency of up to six times in a day. The second seizure type presented with either a right
homonymous hemianopsia or colored balls in the right visual field that occurred several times daily and lasted for
minutes to hours. The third seizure type was described as a feeling of numbness and tingling on the right side of
the body that also occurred several times daily and lasted minutes to hours. Besides seizures the patient also
complained of memory and word finding difficulties; nausea, abdominal discomfort, constipation, migraine
headaches, brief episodes of diaphoresis and palpitations, and blurry vision, which have worsened of over the
last six months.
•General physical exam revealed normal vital signs, obesity and abdominal striae. Neurological examination
revealed abnormalities on mental status including: disorientation to date, fluent speech with word-finding
difficulties, severe anomia with decreased categorical fluency, dyscalculia, alexia with agraphia, ideomotor and
constructional apraxia, poor attention and concentration. Cranial nerve exam was noteworthy for downbeat and
horizontal nystagmus, ocular dysmetria, right homonymous hemianopsia, bilateral tilted and atrophic optic
nerves, and mild right central facial nerve palsy with the rest of the cranial nerves being grossly intact. On
manual motor testing there was a right upper extremity drift with power of 4/5, right lower extremity was 4/5 with
right foot drop, and the left upper and lower extremities were 5/5. Sensation was diminished to pain,
temperature, vibration, and proprioception in all four extremities. On coordination testing the patient was unable
to perform finger-to-nose or heel-to-shin and there was a positive Romberg sign. Gait was unsteady, widebased, and ataxic with the patient leaning more to the right. Reflexes were hypoactive at +1/4 in the upper and
lower extremities. Plantar cutaneous responses were flexor bilaterally with no clonus or pathologic spread.
•Based on the patient’s clinical history of worsening seizures on valproate and multi-systemic symptoms, we
initiated a work-up for a mitochondrial cytopathy and started the patient on 10% dextrose IV with L-carnitine and
coenzyme Q-10. Her valproate was stopped and her seizures were improved with phenytoin. After measuring
high serum lactate and pyruvate levels (Figure 1), the patient was subjected to further testing including:
echocardiogram, muscle biopsy, and routine genetic testing for mitochondrial disorders through Athena labs,
which all came back negative.

•MRI of the brain (Figure 3) revealed T2 hyperintesities in the left thalamus, left parietal and left occipital
. regions,and right cerebellar white matter with corresponding restricted diffusion on DWI, as well as
cortical
associated atrophy of the left parieto-occipital lobe. A continuous 24-hour scalp EEG (Figure 2) with video
revealed frequent interictal parieto-occipital sharp waves in wakefulness and sleep, as well as frequent seizures
with onset in the left parieto-occipital region with patient reporting seeing colored balls in the right visual field
and tingling sensation on the right side of the body. There were also a few seizures detected in the left
posterior temporal region, which were sub- clinical. The differential diagnosis at this point was extended to
include: Rassmusen’s encephalitis, cerebral autosomal dominant arteriopathy with subcortical infarcts and
leukoencephalopathy (CADASIL), familial hemiplegic migraine (FHM), autosomal dominant ataxias,
leukodystrophy, paraneoplastic disorder, as well as infectious, autoimmune, and neurodegenerative etiologies.
Extensive laboratory and diagnostic testing (Figure 1) were performed over a period of several months in the
outpatient setting and excluded the above conditions.
•The patient also had an EMG/NC study which detected the presence of a sensory axonal neuropathy. Routine
neuropathy work-up revealed a vitamin B12 deficiency. The patient was also found to have a vitamin D
deficiency and osteoporosis on a DEXA scan. Endocrine work-up as well as testing of pancreatic enzymes and
celiac disease antibodies was negative. The presence of a wide range of neurological manifestations and
intestinal malabsorption, with elevated levels of serum lactate and pyruvate, prompted further investigation into
a mitochondrial disorder with additional genetic testing that was beyond what was available through the
conventional Athena panel. This genetic test was sent out to a different lab, which identified a compound
heterozygous A467T/W748S mutation in the POLG1 gene. The patient was restarted back on coenzyme Q-10
and continued on phenytoin for her seizures, with lamotrigine added later on. Since her discharge in 2007, her
seizures have become less severe, with only infrequent simple somatosensory and visual focal seizures. She
has also experienced some improvement in her neurological deficits, especially with correction of her vitamin
B12 levels. Follow up MRI of the brain has shown resolution of the high T2 signal abnormalities in various
cortical and subcortical regions, however, prominent left parieto-occipital atrophy remains.
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A: 24 hour scalp EEG with interictal left parieto-occipital sharp waves. B: 24 hour scalp EEG with left
parieto-occipital seizure
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•Based on previous case reports, patients with an A467T/W748S POLG1 mitochondrial disorder may have
cortical and cerebellar atrophy as well as abnormal T2 hyperintensities with restricted diffusion on MRI in
various cortical and subcortical structures including: occipital cortex, deep cerebellar structures, thalamus
(most common), basal ganglia, and inferior olives [4]. Laboratory testing usually reveals increased serum
and CSF lactate, pyruvate as well as positive oligoclonal bands, elevated CSF protein and CSF pleocytosis
[3]. Muscle biopsy may or may not be helpful diagnostically, however, the presence of ragged red fibers
should elevate a mitochondrial cytopathy on the differential.
•The prevalence of epilepsy by POLG1 genotype is –A467T: 100%, W748S: 70%, A467T/W748S: 75% [5].
VEEG monitoring may show simple partial motor seizures, most often involving an arm, shoulder, neck and or
head, as in our patient [5]. Patients with an occipital lobe predilection usually complain of perception of
colored light in one visual hemifield or either a scotoma or a hemianopsia which can persist for hours, days,
weeks, months, or even years [5]. Formed visual hallucinations as well as nystagmus and eye-lid myoclonus
have also been reported [5]. Complex partial seizures (CPS) with motor symptoms have also been
documented in these patients. Patients have been observed to have as part of their CPS (focal jerks, head
turning, motor automatisms as well as visual symptoms). Interestingly, our patient had prominent sensory
symptoms as part of her seizures, referable to a parieto-occipital focus. Previous case reports of
A467T/W748S mutations describe the seizures as having an occipital lobe onset with prominent visual and
motor symptoms.. The MRI brain of our patient demonstrates that POLG1-related cerebral cortical lesions are
not only confined to the occipital areas, as previously described, but also can involve the parietal cortex as
well. Our case report further corroborates that the posterior regions (parieto-occipital lobe) of the brain serve
as the epileptic origin in POLG1-related epilepsy. The reason for why there is a parieto-occipital lobe
predilection is still unknown and remains to be established.
•Combination anti-epileptic therapy, which has been showed to be beneficial for seizure frequency reduction
include: sodium channel blockers (e.g. carbamazepine (CBZ), phenytoin (PHT), oxcarbazepine (OXC) or
lamotrigine [5]. Often these drugs are combined with benzodiazepines. Epilepsy in patients with a POLG1
mutation should be treated very aggressively to prevent a vicious cycle of epileptogenesis, which leads to
seizure refractoriness and ultimately epileptic status, which is the main cause of morbidity and mortality in
these patients [5].
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•Axial T2 MRI brain (A,D,E) with hyperintensities in the left parietal lobe, left thalamus, left occipital lobe,
and right cerebellar hemisphere with corresponding restricted diffusion as seen on the axial DWI MRI brain
(B, C, F). Additional areas of restricted diffusion are seen in the right basal ganglia, left frontal lobe, brain
stem, and splenium of the corpus collosum (B,C,F,G). Prominent parieto-occipital lobe atrophy with high
signal abnormality is seen on sagittal T1brain w/o gad (H).

Discussion
•The POLG1 gene encodes for the human mitochondrial DNA polymerase [4]. Mutations in the POLG1 gene
can cause autosomal dominant and recessive chronic progressive external ophthalmoplegia (CPEO), Alpers’
syndrome, sensory ataxic neuropathy, dysarthria, and ophthalmoparesis (SANDO), parkinsonism, and a
mitochondrial recessive ataxic syndrome [4]. The majority of mutations in the POLG1 gene cause CPEO,
however, two mutations, the 1399G/A and 2243G/C giving the amino acid substitutions A467T and W748S,
respectively, cause a recessive mitochondrial ataxic syndrome, which is what we suspect our patient had [4].
•The age of onset of neurological symptoms in patients with POLG1 mutations ranges from 2-36, with most
starting in their teens [4]. Irrespective of genotype, patients exhibit a progressive neurological disorder
characterized by epilepsy, headache, ataxia, neuropathy, myoclonus, and late onset ophthalmoplegia. The
epilepsy often occurs in combination with headaches that have features of migraine [4]. Patients with POLG1
gene mutations are at high risk of death from status epilepticus and from liver failure, especially if exposed to
sodium valproate [4]. Kaplan-Meier survival analysis from small case series shows that compound
heterozygous patients do significantly worse than those who are homozygous either for the A467T/A467T or
W748S/W748S [4]. Median survival for patients with A467T/A467T, A467T/W748S, and W748S/W748S
mutations is 50, 6, and 26 months respectively [4]. Despite this dire statistic, our patient, who is currently
more than two years from her diagnosis, is clinically doing well.

•This is a rare case of a POLG1 gene mutation with a wide range of neurological manifestations. The gradual
onset of symptoms as well as multi-organ involvement made the diagnosis difficult. The focal seizures were
the initial manifestation of the disease and the patient was thought to have cryptogenic focal epilepsy. Multiorgan involvement and worsening of the symptoms on valproate raised the concern for mitochondrial disease.
However, conventional work up for mitochondrial disease using the genetic panel run through Athena was
negative, making the diagnosis more challenging and resulting in more extensive testing for metabolic,
degenerative, paraneoplastic, and infectious disorders. Our case report helps to illustrate the key clinical
features associated with POLG1 mutations, specifically the A467T/W748S, which if recognized by
neurologists can help focus the investigation on POLG1 and make it unnecessary to investigate mtDNA
genes. In addition to advocating for aggressive epilepsy treatment for these patients, we also recommend
good nutrition; particularly close follow-up, and supplements such as L-carnitine and coenzyme-Q10.
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